Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Cefiderocol + xeruborbactam) by Qpex Biopharma for Gram-Negative Bacterial Infections: Likelihood of Approval
(Cefiderocol + xeruborbactam) is under clinical development by Qpex Biopharma and currently in Phase I for Gram-Negative Bacterial Infections. According...